Gene Signal International SA
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Gene Signal International SA
Although visual acuity is no longer thought to be a useful primary endpoint for drugs targeting corneal neovascularization, Gene Signal will keep developing its first-in-class antisense product in that and other ophthalmic indications.
A topical antisense product, aganirsen, from Switzerland’s Gene Signal is to be evaluated in neovascular glaucoma, age-related macular degeneration and psoriasis following the completion of a Phase III study in corneal graft rejection.
Derived from Strategic Transactions, Elsevier Business Intelligence’s premium source for tracking life sciences deal activity, the Recent Financings Of Start-Ups column provides a comprehensive monthly review of emerging life science companies that have received venture funding, including companies within the In Vitro Diagnostics, Medical Devices, and Pharmaceuticals sectors.
Having completed its latest private funding round, Lausanne, Switzerland-based biotech firm, Gene Signal said it is set to embark on an 'aggressive' three-year clinical and commercialization plan for its angiogenesis therapies.